journal article·2023-09-12Open access

Patterns of Carbon-Bound Exogenous Compounds Impact Disease Pathophysiology in Lung Cancer Subtypes in Different Ways

Jian Shen, Na Sun, Jun Wang, Philipp Zens, Thomas Kunzke, Achim Buck, Verena M. Prade, Qian Wang, Annette Feuchtinger, Ronggui Hu, Sabina Berezowska, Axel Walch

ACS Nano· Volume 17· Issue 17

Abstract

Carbon-bound exogenous compounds, such as polycyclic aromatic hydrocarbons (PAHs), tobacco-specific nitrosamines, aromatic amines, and organohalogens, are known to affect both tumor characteristics and patient outcomes in lung squamous cell carcinoma (LUSC); however, the roles of these compounds in lung adenocarcinoma (LUAD) remain unclear. We analyzed 11 carbon-bound exogenous compounds in LUAD and LUSC samples using in situ high mass-resolution matrix-assisted laser desorption/ionization Fourier-transform ion cyclotron resonance mass spectrometry imaging and performed a cluster analysis to compare the patterns of carbon-bound exogenous compounds between these two lung cancer subtypes. Correlation analyses were conducted to investigate associations among exogenous compounds, endogenous metabolites, and clinical data, including patient survival outcomes and smoking behaviors. Additionally, we examined differences in exogenous compound patterns between normal and tumor tissues. Our analyses revealed that PAHs, aromatic amines, and organohalogens were more abundant in LUAD than in LUSC, whereas the tobacco-specific nitrosamine nicotine-derived nitrosamine ketone was more abundant in LUSC. Patients with LUAD and LUSC could be separated according to carbon-bound exogenous compound patterns detected in the tumor compartment. The same compounds had differential impacts on patient outcomes, depending on the cancer subtype. Correlation and network analyses indicated substantial differences between LUAD and LUSC metabolomes, associated with substantial differences in the patterns of the carbon-bound exogenous compounds. These data suggest that the contributions of these carcinogenic compounds to cancer biology may differ according to the cancer subtypes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Metabolomics and Mass Spectrometry Studies · Lung Cancer Diagnosis and Treatment · Lung Cancer Treatments and Mutations

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Research Unit Analytical Pathology, Helmholtz Zentrum München − German Research Center for Environmental Health, Neuherberg 85764, Germany

Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Institute of Pathology, Guilin 541002, People’s Republic of China

Institute of Tissue Medicine and Pathology, University of Bern, Murtenstrasse 31, Bern 3008, Switzerland

Graduate School for Health Sciences, University of Bern, Mittelstrasse 43, Bern 3012, Switzerland

Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200030, People’s Republic of China

Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne 1011, Switzerland

Funding

Bundesministerium f?r Bildung und Forschung · Swiss Cancer Research Foundation · Deutsche Forschungsgemeinschaft · Deutsche Krebshilfe · Stiftung zur Krebsbek?mpfung

References (100+)

Show source-provided references
1. 10.1016/j.envres.2019.03.00610.1016/j.envres.2019.03.006 ↗
2. 10.1080/15287394.2011.55605910.1080/15287394.2011.556059 ↗
3. 10.1002/anie.20210387410.1002/anie.202103874 ↗
4. 10.1021/es901433m10.1021/es901433m ↗
5. 10.1021/nn406484b10.1021/nn406484b ↗
6. 10.1039/C4NR06175F10.1039/C4NR06175F ↗
7. 10.1186/s12989-018-0250-810.1186/s12989-018-0250-8 ↗
8. 10.4997/jrcpe.2019.21910.4997/jrcpe.2019.219 ↗
9. 10.1097/00000478-200209000-0001010.1097/00000478-200209000-00010 ↗
10. 10.1016/0041-008X(84)90052-810.1016/0041-008X(84)90052-8 ↗
11. 10.1016/j.taap.2020.11539110.1016/j.taap.2020.115391 ↗
12. 10.1016/j.envint.2023.10784510.1016/j.envint.2023.107845 ↗
13. 10.1158/0008-5472.CAN-21-117510.1158/0008-5472.CAN-21-1175 ↗
14. 10.1038/s41467-022-29444-910.1038/s41467-022-29444-9 ↗
15. 10.1056/NEJMra080271410.1056/NEJMra0802714 ↗
16. 10.1038/nrc377510.1038/nrc3775 ↗
17. 10.18632/oncotarget.1760610.18632/oncotarget.17606 ↗
18. 10.3892/mmr.2016.542010.3892/mmr.2016.5420 ↗
19. Zhan C. · J. Thorac. Dis. · 2015 · 7 · 1398
20. 10.1038/ng.356410.1038/ng.3564 ↗
21. 10.1038/s41568-018-0024-510.1038/s41568-018-0024-5 ↗
22. 10.1016/j.rcl.2012.06.00610.1016/j.rcl.2012.06.006 ↗
23. 10.1016/j.tranon.2017.01.01510.1016/j.tranon.2017.01.015 ↗
24. Daraselia N. · Am. J. Cancer Res. · 2012 · 2 · 93
25. 10.1158/1078-0432.CCR-15-290010.1158/1078-0432.CCR-15-2900 ↗
26. 10.4238/2014.January.8.810.4238/2014.January.8.8 ↗
27. 10.1038/nature2518310.1038/nature25183 ↗
28. 10.1056/NEJMoa161628810.1056/NEJMoa1616288 ↗
29. 10.1021/cr300429510.1021/cr3004295 ↗
30. 10.1038/nprot.2016.08110.1038/nprot.2016.081 ↗
31. 10.1016/j.clinbiochem.2013.01.01810.1016/j.clinbiochem.2013.01.018 ↗
32. 10.1002/cac2.1231010.1002/cac2.12310 ↗
33. 10.1158/1078-0432.CCR-21-438310.1158/1078-0432.CCR-21-4383 ↗
34. 10.3390/cancers1313331410.3390/cancers13133314 ↗
35. 10.1164/rccm.200602-301OC10.1164/rccm.200602-301OC ↗
36. 10.1016/S0169-5002(03)00035-710.1016/S0169-5002(03)00035-7 ↗
37. 10.1016/j.ijpharm.2013.10.03810.1016/j.ijpharm.2013.10.038 ↗
38. 10.1016/j.drudis.2019.09.02310.1016/j.drudis.2019.09.023 ↗
39. 10.3390/ijms2109324810.3390/ijms21093248 ↗
40. 10.3390/nano503135110.3390/nano5031351 ↗
41. 10.1021/ar300031y10.1021/ar300031y ↗
42. Zlobec I. · J. Visualized Exp. · 2014 · 51893
43. 10.1093/nar/gkr113210.1093/nar/gkr1132 ↗
44. 10.1093/nar/gkx108910.1093/nar/gkx1089 ↗
45. 10.1016/j.apsb.2021.05.01510.1016/j.apsb.2021.05.015 ↗
46. 10.1016/j.chroma.2021.46279510.1016/j.chroma.2021.462795 ↗
47. Tannock I. F. · Cancer Res. · 1989 · 49 · 4373
48. 10.3390/polym1210228910.3390/polym12102289 ↗
49. 10.1021/acsomega.7b0203510.1021/acsomega.7b02035 ↗
50. 10.1016/0300-483X(85)90031-910.1016/0300-483X(85)90031-9 ↗
51. 10.1016/j.scitotenv.2015.04.04810.1016/j.scitotenv.2015.04.048 ↗
52. 10.3390/ijerph1811569910.3390/ijerph18115699 ↗
53. 10.1016/0095-8522(60)90037-410.1016/0095-8522(60)90037-4 ↗
54. 10.20892/j.issn.2095-3941.2019.018010.20892/j.issn.2095-3941.2019.0180 ↗
55. 10.1016/0006-2952(95)02072-110.1016/0006-2952(95)02072-1 ↗
56. 10.1038/nrc119010.1038/nrc1190 ↗
57. Rodgman A. · 2009
58. 10.1007/BF0041244110.1007/BF00412441 ↗
59. 10.1038/nature2235910.1038/nature22359 ↗
60. 10.2741/223210.2741/2232 ↗
61. 10.1186/s12967-020-02286-z10.1186/s12967-020-02286-z ↗
62. 10.1016/j.molmed.2019.04.01210.1016/j.molmed.2019.04.012 ↗
63. 10.1186/s11671-015-0923-210.1186/s11671-015-0923-2 ↗
64. 10.2147/IJN.S38855710.2147/IJN.S388557 ↗
65. 10.3109/1040844100374289510.3109/10408441003742895 ↗
66. 10.1093/carcin/bgy05910.1093/carcin/bgy059 ↗
67. 10.1186/1479-5876-8-8610.1186/1479-5876-8-86 ↗
68. 10.1016/j.lungcan.2009.11.00210.1016/j.lungcan.2009.11.002 ↗
69. 10.18632/aging.10412910.18632/aging.104129 ↗
70. 10.18632/aging.10406210.18632/aging.104062 ↗
71. 10.1093/toxsci/kft12810.1093/toxsci/kft128 ↗
72. 10.1158/0008-5472.CAN-12-081810.1158/0008-5472.CAN-12-0818 ↗
73. Su J. M. · Anticancer Res. · 2013 · 33 · 3953
74. 10.1038/s41467-019-08887-710.1038/s41467-019-08887-7 ↗
75. 10.1073/pnas.97.2.77910.1073/pnas.97.2.779 ↗
76. 10.1002/ijc.2434810.1002/ijc.24348 ↗
77. 10.1002/mc.2070210.1002/mc.20702 ↗
78. 10.1158/1541-7786.MCR-12-021610.1158/1541-7786.MCR-12-0216 ↗
79. 10.1158/1541-7786.MCR-16-006910.1158/1541-7786.MCR-16-0069 ↗
80. 10.3390/cells904103110.3390/cells9041031 ↗
81. 10.1158/1078-0432.CCR-06-289810.1158/1078-0432.CCR-06-2898 ↗
82. 10.1016/j.canlet.2011.12.00810.1016/j.canlet.2011.12.008 ↗
83. 10.1021/acsnano.5b0370810.1021/acsnano.5b03708 ↗
84. 10.1186/1743-8977-9-810.1186/1743-8977-9-8 ↗
85. 10.1038/s41392-022-01130-810.1038/s41392-022-01130-8 ↗
86. 10.1016/j.scitotenv.2020.14355310.1016/j.scitotenv.2020.143553 ↗
87. 10.1021/es048182a10.1021/es048182a ↗
88. 10.1021/es703107w10.1021/es703107w ↗
89. 10.1097/JTO.0b013e318206a22110.1097/JTO.0b013e318206a221 ↗
90. 10.1146/annurev.pathol.1.110304.10010310.1146/annurev.pathol.1.110304.100103 ↗
91. 10.13075/mp.5893.0094410.13075/mp.5893.00944 ↗
92. Jamaati H. · Asian Pac. J. Cancer Prev. · 2017 · 18 · 3129
93. 10.1016/S1470-2045(13)70279-110.1016/S1470-2045(13)70279-1 ↗
94. 10.1038/s12276-020-0405-110.1038/s12276-020-0405-1 ↗
95. 10.1038/nature1552910.1038/nature15529 ↗
96. 10.3389/fonc.2018.0001510.3389/fonc.2018.00015 ↗
97. 10.3389/fonc.2020.0125610.3389/fonc.2020.01256 ↗
98. 10.1038/s41598-020-77284-810.1038/s41598-020-77284-8 ↗
99. 10.1038/sj.onc.120164710.1038/sj.onc.1201647 ↗
100. 10.1093/jnci/92.10.80310.1093/jnci/92.10.803 ↗